Huntington’s Disease – Global Clinical Trial Pipeline Highlights, 2019 – ResearchAndMarkets.com
June 10, 2019DUBLIN–(BUSINESS WIRE)–The “Huntington’s
Disease – Global Clinical Trial Pipeline Highlights, 2019”
report has been added to ResearchAndMarkets.com’s
offering.
This report provides most up-to-date information on key pipeline
products in the global Huntington’s Disease market. It covers emerging
therapies for Huntington’s Disease in active clinical development stages
including early and late stage clinical trials.
The pipeline data presented in this report helps executives for tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.
Clinical Trial Stages
The report provides Huntington’s Disease pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes
The report provides Huntington’s Disease pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.
Company
The report provides Huntington’s Disease pipeline products by the
company.
Short-term Launch Highlights
Find out which Huntington’s Disease pipeline products will be launched
in the US and Ex-US till 2024.
Key Topics Covered
1. Huntington’s Disease Pipeline by Stages
2. Huntington’s Disease Phase 3 Clinical Trial Insights
3. Huntington’s Disease Phase 2 Clinical Trial Insights
4. Huntington’s Disease Phase 1 Clinical Trial Insights
5. Huntington’s Disease Preclinical Research Insights
6. Huntington’s Disease Discovery Stage Insights
7. Appendix
8. Research Methodology
List of Tables
Table 1: Huntington’s Disease Phase 3 Clinical Trials, 2019
Table 2: Huntington’s Disease Phase 2 Clinical Trials, 2019
Table 3: Huntington’s Disease Phase 1 Clinical Trials, 2019
Table 4: Huntington’s Disease Preclinical Research, 2019
Table 5: Huntington’s Disease Discovery Stage, 2019
List of Figures
Figure 1: Huntington’s Disease Pipeline Molecules by Clinical Trials
Stage, 2019
Figure 2: Huntington’s Disease Phase 3 Clinical Trial Highlights, 2019
Figure 3: Huntington’s Disease Phase 2 Clinical Trial Highlights, 2019
Figure 4: Huntington’s Disease Phase 1 Clinical Trial Highlights, 2019
Figure 5: Huntington’s Disease Preclinical Research Highlights, 2019
Figure 6: Huntington’s Disease Discovery Stage Highlights, 2019
For more information about this report visit https://www.researchandmarkets.com/r/jp0evq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs, Clinical
Trials